retatrutide clinical trials weight loss retatrutide A New Obesity Drug Delivered Surgery-Level in When will Retatrutide be available

2 Kidney Disease Risk Reduction In addition, the FDA has approved semaglutide (Ozempic) to slow the progression of kidney disease and reduce the risk of kidney failure, making it the most widely indicated GLP-1 drug

When food remains in the stomach for extended periods of time, patients may develop severe nausea, vomiting, dehydration, malnutrition, abdominal swelling, and painful digestive complications requiring hospitalization or emergency treatment

Gallbladder Disease: Increased risk of gallstones, especially in individuals with existing gallbladder problems

All content is for educational purposes only.

It simultaneously activates GLP-1, GIP, and glucagon receptors making it the first tri-agonist in its class

It links degradation to reduced appetite suppression, diminished weight loss outcomes, and inconsistent glucose control